Science solved the hard part. Keeping people safe from HIV is no longer a biological mystery, yet thousands remain locked out of life-saving medicine.
In clinical trials involving young women across South Africa and Uganda, zero participants who received lenacapavir contracted HIV. Twice a year. That is all it takes. Two injections annually replace the grueling daily pill routine of standard pre-exposure prophylaxis, commonly known as PrEP. Medical experts call it the closest thing to an actual HIV vaccine we have ever seen.
So why are public health advocates sounding alarms instead of celebrating? Because a brilliant medical breakthrough trapped behind corporate patents and arbitrary geographic lines helps nobody.
The Access Gap and Who Gets Left Behind
Let's look at the numbers. In the United States, Gilead Sciences prices lenacapavir at roughly $28,000 per person annually. Meanwhile, generic alternatives are projected to cost around $40 a year. That massive gulf creates an immediate global apartheid in healthcare.
Gilead licensed six manufacturers to produce lower-cost generics, aiming for a large-scale rollout by 2027. Sounds promising, right? Except the fine print tells a darker story. At least 26 middle-income countries are completely excluded from these generic agreements. Nations like Brazil, Mexico, Argentina, and Peru—places that actively helped clinical trials generate the evidence required to approve the drug—find themselves shut out of affordable generic access.
Excluded countries accounted for nearly 23 percent of all new HIV infections globally in recent years. Tell those patients that geography dictates their survival.
Humanitarian Crises Don't Wait for Corporate Rollouts
Medical humanitarian organizations like Doctors Without Borders (MSF) face brick walls when trying to secure supplies. For over a year, MSF requested permission to buy lenacapavir directly from Gilead for humanitarian projects, offering to pay standard costs rather than deep discounts. Gilead flatly refused direct sales to the organization.
Think about what that means on the ground. People displaced by violent conflicts or natural disasters cannot reliably swallow a pill every single day. A twice-yearly shot protects vulnerable populations facing heightened risks of sexual violence and displacement. When medical gatekeepers block organizations from purchasing approved treatments, human lives become collateral damage.
Gilead defended its approach by pointing to no-profit supplies for specific programs like PEPFAR and the Global Fund, alongside separate regional pathways for Latin American countries. But international funding for HIV dropped sharply, hitting $7.3bn recently—its lowest level in nearly twenty years. Relying on charity supply pipelines while cutting back overall funding is a recipe for disaster. Projections show roughly 20 million people worldwide need PrEP access to curb new infections. Current manufacturer targets fall woefully short.
How Governments Can Bypass the Barriers
Are countries just supposed to sit back and accept high prices or total exclusion? Absolutely not. International trade laws already provide legal tools designed for public health emergencies.
Under World Trade Organization rules, governments hold the legal right to issue compulsory licenses. This allows a country to authorize the production or importation of a cheaper generic medicine without the patent holder's permission. Brazil famously deployed this exact playbook back in 2007, forcing a breakthrough on HIV treatment costs when negotiations stalled with pharmaceutical giant Merck.
Activist groups are pushing Brazil and other excluded nations to dust off those legal safeguards for lenacapavir. If corporate monopolies threaten public health, governments possess the sovereignty to override them.
Breakthrough science loses its value if it serves as a luxury product for wealthy nations. Real innovation requires distribution systems built around human need rather than profit margins. Stop treating life-saving medicine like a luxury asset.
